BrainCool AB (publ)
BRAIN.ST
Stockholm Stock Exchange0.85
SEK
+0.04
- -
BrainCool AB (publ)
BRAIN.ST
(Stockholm Stock Exchange)
Recent
price
0.85
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BrainCool AB (publ) is a Sweden-based medical device company specializing in the development, marketing, and sale of advanced medical cooling systems for the healthcare sector. The company's core products include the BrainCool System, a closed-loop temperature management system that monitors and controls patient temperature at anatomical zones including the head/neck, thighs, and torso; the RhinoChill System, a portable, battery-powered nasal cooling device for emergency use; the Cooral® System, designed to reduce the risk of oral mucositis in cancer patients undergoing chemotherapy; and the IQool System, a single-use silicone cooling pad system used for patient care. These products target medical cooling treatments for conditions such as stroke, cardiac arrest, neurological fever, concussion, migraine, chemotherapy side effects, and oral mucositis. BrainCool’s technology is based on cooling pads and systems that enable precise temperature control to improve patient outcomes. Founded in 2010, BrainCool AB is headquartered in Lund, Sweden, and operates primarily within the healthcare and medical device industry. Its products serve hospitals, clinics, and healthcare providers in Sweden and internationally, with an expanding footprint supported by research, development, and clinical collaborations. The company’s product portfolio supports critical care pathways from pre-hospital emergency treatment with RhinoChill to ongoing hospital-based temperature management and oncology supportive care systems like Cooral®. In the past 1-2 years, BrainCool AB has made several strategic advancements including the launch of the Cooral® System, which received US FDA De Novo clearance, representing a significant milestone in oncology supportive care. The company also introduced MiniChill, a lighter and more portable version of the RhinoChill System, facilitating easier transport and handling in emergency medical services. Additionally, BrainCool undertook a SEK 42 million rights issue to strengthen its financial position and support further research and development. The company continues to deepen partnerships with clinical institutions, exemplified by deliveries of their cooling systems to hospitals like Karolinska Institutet for major cardiac arrest studies, highlighting its focus on expanding its product application and clinical evidence base. BrainCool AB is publicly listed on Nasdaq First North Growth Market under the ticker BRAIN.ST. The company maintains a focus on innovation in medical cooling technology with a commitment to broadening indications, improving patient care quality, and expanding its global market presence through ongoing product development and strategic collaborations. This comprehensive focus on specialized medical cooling solutions positions BrainCool AB as a leading player in hypothermia and temperature management treatment technologies within the healthcare sector.